Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib
Year: 2015
Type: article
Abstract: Had Been Receiving RociletinibThird-generation EGFR tyrosine kinase inhibitors (TKIs) that block activating EGFR mutations and the T790M resistance mutation yield marked responses among patients with EGFR mutation-positive lung cancer and acquired resistance to initial TKIs.1,2 Osimertinib (formerly AZD9291) was recently approved by the US Food and Drug Administration, and rociletinib (formerly CO-1686) is under regulatory consideration.Little is known about using third-generation EGFR inhibitors sequentially.
Source: JAMA Oncology
Institutions: Harvard University, Massachusetts General Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Award: G6929043217
OpenAlex ID: W2207941545